Astellas Targets 5 Percent Annual Sales Increase In North America
This article was originally published in PharmAsia News
Executive Summary
Japan's second largest drug maker Astellas is optimistic about sales growth in the North American market. The company aims to achieve an annual 5 percent increase and estimates a strong demand for the overactive bladder drug Vesicare (solifenacin), Astellas U.S. President Yoshihiko Hatanaka said during a Tokyo briefing Aug. 28. According to Hatanaka, the U.S. market for Vesicare is estimated to grow 44 percent to $349 million in 2008. The strong growth could help offset estimated decreased sales in Astellas' blockbuster immunosuppressant Prograf (tacrolimus), which has gone off-patent in the U.S. (Click here fore more - Japanese language)
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.